Clinical Features and Prognosis of Rabdomiosarcoma in Children

Authors

  • Helmi Ismunandar Universitas Lampung
  • Rani Himayani Universitas Lampung
  • Diki Prawira Adifa Universitas Lampung

DOI:

https://doi.org/10.53089/medula.v10i4.158

Keywords:

Diagnostic, Prognostic, Rhabdomyosarcoma

Abstract

Rhabdomyosarcoma is a soft tissue malignancy with prevalences about 5% of all malignancies in children and 20% of soft tissue malignancies that occur in children. The most common primary tumor sites include the head and neck area followed by the genitourinary and extremities. Meanwhile, the most common subtypes are embryonic in children and alveolar in adolescents. Although the specific etiology for RMS is largely unknown, there are increased risk factors for environmental factors such as radiation and drugs, syndromes, and chromosomal abnormalities. The clinical symptoms vary and are related to the location of the mass and the blockage it caused. Histopathological and immunohistochemical examinations are gold standard tests for diagnosing RMS and determining subtypes that serve as prognosis and therapy. Various therapeutic approaches can be surgery, chemotherapy, radiotherapy, or in a combination.

References

Desen W. Buku ajar onkologi klinis edisi 2. Jakarta : Balai penerbit FKUI; 2013.

Ognjanovic S, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, Mueller BA, Puumala S, Reynolds P, Von Behren J, Spector L. Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer. 2010 Jan 05;102(1):227-31

Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol. 2009 Jul 10; 27(20): p3391-7.

Wexler LH, Skapek SX, Helman LJ. Capter 31; Rhabdomyosarcoma. In; Pizzo PA, Poplack DG, eds. Principles and practice of pediatrc oncology 7th ed. Philadelphia Lippincott Williams and Wilkins; 2016.

Rini AT, Gatot D, Windiastuti E, Ciputra Y. Rabdomiosarkoma pada anak; gambaran klinis di 2 institusi. Indonesian journal of cancer;2008, 55-59

Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med; 2015 Dec 10; 373(24): p2336-46.

Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone 4th ed. Lyon, France: International Agency for Research on Cancer; 2013. World Health Organization Classification of Tumours; vol 5

Duan F, Smith LM, Gustafson DM, Zhang C, Dunlevy MJ, Gastier-Foster JM, et al.. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma. A Report from the Children Oncology Group. Genes chromosomes cancer; 2012

Okcu MF, Hicks J. Rhabdomyosarcoma in childhood and adolescence; clinical presentation, diagnostic evaluation, and staging; 2018

HE Shinta , ni putu sriwidyani. Laporan kasus Embryonal rhabdomiosarcoma. Departemen patologi anatomi, FK UNUD Denpasar, Bali. 2019.

Suman M and Douglas SH. Rhabdomyosarcoma: review of the children’s oncology group (COG) soft-tissue sarcoma committee experience and rationale for current COG studies. Pediatr Blood Cancer; 2012 Jul 15; 59(1): p5–10.

Pudjiadi AH, Hegar B, Handryastuti S, Salamia N, Idris EP, Eva G, Harmoniati D, Yuliarti K. Rabdomiosarkoma dalam pedoman pelayanan medis jilid II. Ikatan Dokter Anak Indonesia; 2011; p249-50

Gallego MS, Sánchez TCJ. Rhabdomyosarcoma: present and future perspectives in diagnosis and treatment. Clin Transl Oncol. 2005 Jan-Feb;7(1): p35-41

Xinxin Z , Kun M, Jaling W, Wenming W, Lin M, Deliang H. A prospective evaluation of the combined helical tomotherapy and chemotherapy in pediatric patients with unresectable rhabdomyosarcoma of the temporal bone. Cell biochem biophys; 2014 Sep;70(1): p103-8. doi: 10.1007/s12013-014-9864-0.

Sebire NJ, Malone M. Myogenin and myo D1 expression in Paedriatic Rhabdomyosarcomas. J.Clin Pathol; 2003; 56; p412-16

Leaphart C, Rodeberg D. Pediatric surgical oncology: management of rhabdomyosarcoma. Surg Oncol; 2007 Nov; 16(3): p173-85.

Affinita MC, Ferrari A, Milano GM, et al.. Longterm result in children with head and neck rhabdomyosarcoma; a report from the italian soft tissue sarcome commitee. Pediatr blood cancer; 2018.

Sung L, Anderson JR, Donaldson SS, et al.: Late events occurring five years or more after successful therapy for childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Eur J Cancer; 2004 vol 40 (12): p1878-85,.

Joffe L, Dwyer S, Glade Bender JL, Frazier AL, Ladas EJ. Nutritional status and clinical outcomes in pediatrc patients with solid tumors; a systematic review of literature. Semin Oncol; 2018.

Smith LM, Anderson JR, Qualman SJ, et al. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group. J Clin Oncol 19; 2001 (20): p4058-64.

Novelin R, Abdah E, Restuastuti T. Gambaran penderita rabdomiosarkoma di bagian bedah rsud arifin achmad provinsi riau periode januari 2007-desember 2012. Bagian Ilmu Kesehatan Masyarakat Universitas Riau; 2013.

Published

2021-02-01

How to Cite

Helmi Ismunandar, Rani Himayani, & Diki Prawira Adifa. (2021). Clinical Features and Prognosis of Rabdomiosarcoma in Children. Medical Profession Journal of Lampung, 10(4), 581-587. https://doi.org/10.53089/medula.v10i4.158

Issue

Section

Artikel

Most read articles by the same author(s)

1 2 > >>